Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
User-agent: * Disallow: |
Title | Sanofi Genzyme | Unlocking a Brighter Path in Metastatic Breast Cancer |
Description | COULD ADVANCEMENTS IN ER ANTAGONISM OR DEGRADATION UNLOCK A Can we unlock a brighter path for patients with ER+/HER2- metastatic breast cancer? Further research may help delay disease |
Keywords | N/A |
WebSite | unlockmbc.info |
Host IP | 54.247.151.159 |
Location | Ireland |
Site | Rank |
US$1,365
Last updated: 2022-11-24 17:13:53
unlockmbc.info has Semrush global rank of 0. unlockmbc.info has an estimated worth of US$ 1,365, based on its estimated Ads revenue. unlockmbc.info receives approximately 157 unique visitors each day. Its web server is located in Ireland, with IP address 54.247.151.159. According to SiteAdvisor, unlockmbc.info is safe to visit. |
Purchase/Sale Value | US$1,365 |
Daily Ads Revenue | US$1 |
Monthly Ads Revenue | US$37 |
Yearly Ads Revenue | US$453 |
Daily Unique Visitors | 10 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
unlockmbc.info. | A | 900 | IP: 54.247.151.159 |
unlockmbc.info. | NS | 900 | NS Record: ns4.sanofi-synthelabo.com. |
unlockmbc.info. | NS | 900 | NS Record: ns1.sanofi-synthelabo.com. |
unlockmbc.info. | NS | 900 | NS Record: ns2.sanofi-synthelabo.com. |
unlockmbc.info. | NS | 900 | NS Record: ns3.sanofi-synthelabo.com. |
For Healthcare Professionals Only ✕ Menu HOME ER ACTIVATION ADVANCES IN ER RESEARCH ABOUT SANOFI GENZYME IN ER+/HER2- METASTATIC BREAST CANCER (mBC) COULD ADVANCEMENTS IN ER ANTAGONISM OR DEGRADATION UNLOCK A BRIGHTER FUTURE? See the research Watch MOD video ER ACTIVATION ER+/HER2- tumour cells depend on different kinds of oestrogen receptor (ER) signaling activity to survive 1,2 Complex and often compensatory mechanisms within ER-dependent and -independent pathways enable tumour activation and proliferation 1-3 ER Pathway Activity Is Common 79% OF BREAST CANCER PATIENTS ARE ER+ 4 ~90% of resistant mBC tumours rely on ER-dependent activity 5 ~50% of patients do not respond to initial endocrine therapy 6,7 >300 proteins interact with one or more receptor types, including the ER 8 ER Pathway Activation Is Fueling Resistance Both ER-dependent and -independent pathways are involved in tumour progression and treatment escape mechanisms 2,9 In a series of downstream effects, aberrant |
HTTP/1.1 301 Moved Permanently Date: Sat, 18 Jun 2022 08:32:49 GMT Server: Apache/2.4.48 () Location: https://www.unlockmbc.info/ Content-Type: text/html; charset=iso-8859-1 HTTP/2 200 content-type: text/html; charset=UTF-8 content-length: 76135 date: Sat, 18 Jun 2022 08:32:49 GMT server: AmazonS3 last-modified: Fri, 17 Dec 2021 20:12:17 GMT x-amz-version-id: vtO0W47i_F3FHDJ0kkplZ.CXtJfSusU5 etag: "c54e84ead44b1c73c9e23599209a889d" vary: Accept-Encoding x-cache: Miss from cloudfront via: 1.1 1c104af9dcb33e29b8c5ed9ebabafb86.cloudfront.net (CloudFront) x-amz-cf-pop: HEL51-P1 x-amz-cf-id: 8d3DPkc6GIYCBelzs0y2Z10DIlpdzIWPmVp960FfBykkWOcYg3bpKQ== |
Domain Name: unlockmbc.info Registry Domain ID: df4f82ef8dba4a50b57d7cc69b8bf9cf-DONUTS Registrar WHOIS Server: www.whois.corporatedomains.com Registrar URL: http://www.cscglobal.com Updated Date: 2021-06-25T20:32:38Z Creation Date: 2021-04-26T08:38:41Z Registry Expiry Date: 2023-04-26T08:38:41Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: +1.3026365400 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Registrant Organization: Sanofi Registrant State/Province: FR Registrant Country: FR Name Server: ns1.sanofi-synthelabo.com Name Server: ns2.sanofi-synthelabo.com Name Server: ns3.sanofi-synthelabo.com Name Server: ns4.sanofi-synthelabo.com DNSSEC: unsigned >>> Last update of WHOIS database: 2022-06-18T08:28:11Z <<< |